Selected research
Market Outlook & Growth Opportunities
Global Fractionated Plasma Products Market Outlook and Growth Opportunities 2026
Market perspective
The global Fractionated Plasma Products market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Fractionated Plasma Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Fractionated Plasma Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Fractionated Plasma Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Fractionated Plasma Products market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Fractionated Plasma Products market include Takeda, Weiguang Bio, Tiantan Bio, Hualan Bio, Yuanda Shuyang, Shuanglin Bio, RAAS, Octapharma and Nanyue Bio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Fractionated Plasma Products market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Fractionated Plasma Products and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Fractionated Plasma Products revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Fractionated Plasma Products market.
Fractionated Plasma Products Segment by Company
Takeda
Weiguang Bio
Tiantan Bio
Hualan Bio
Yuanda Shuyang
Shuanglin Bio
RAAS
Octapharma
Nanyue Bio
LFB Group
KM Biologics
Kedrion
Grifols
CSL
CBPO
BPL
Boya Bio
Biotest
Fractionated Plasma Products Segment by Type
Coagulation Factor
Immune Globulin
Albumin
Other
Fractionated Plasma Products Segment by Application
Immunology
Hematology
Other
Fractionated Plasma Products Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Fractionated Plasma Products status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Fractionated Plasma Products key companies, revenue, market share, and recent developments.
3. To split the Fractionated Plasma Products breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Fractionated Plasma Products market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Fractionated Plasma Products significant trends, drivers, influence factors in global and regions.
6. To analyze Fractionated Plasma Products competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fractionated Plasma Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Fractionated Plasma Products and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fractionated Plasma Products.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Fractionated Plasma Products industry.
Chapter 3: Detailed analysis of Fractionated Plasma Products company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Fractionated Plasma Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Fractionated Plasma Products in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Coagulation Factor
- Immune Globulin
- Albumin
- Other
Applications
- Immunology
- Hematology
- Other
Companies covered
- Takeda
- Weiguang Bio
- Tiantan Bio
- Hualan Bio
- Yuanda Shuyang
- Shuanglin Bio
- RAAS
- Octapharma
- Nanyue Bio
- LFB Group
- KM Biologics
- Kedrion
- Grifols
- CSL
- CBPO
- BPL
- Boya Bio
- Biotest
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Fractionated Plasma Products Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Fractionated Plasma Products Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Fractionated Plasma Products Market Dynamics
- 2.1 Fractionated Plasma Products Industry Trends
- 2.2 Fractionated Plasma Products Industry Drivers
- 2.3 Fractionated Plasma Products Industry Opportunities and Challenges
- 2.4 Fractionated Plasma Products Industry Restraints
3 Fractionated Plasma Products Market by Company
- 3.1 Global Fractionated Plasma Products Company Revenue Ranking in 2025
- 3.2 Global Fractionated Plasma Products Revenue by Company (2021-2026)
- 3.3 Global Fractionated Plasma Products Company Ranking (2024-2026)
- 3.4 Global Fractionated Plasma Products Company Manufacturing Base and Headquarters
- 3.5 Global Fractionated Plasma Products Company Product Type and Application
- 3.6 Global Fractionated Plasma Products Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Fractionated Plasma Products Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Fractionated Plasma Products Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Fractionated Plasma Products Market by Type
- 4.1 Fractionated Plasma Products Type Introduction
- 4.1.1 Coagulation Factor
- 4.1.2 Immune Globulin
- 4.1.3 Albumin
- 4.1.4 Other
- 4.2 Global Fractionated Plasma Products Sales Value by Type
- 4.2.1 Global Fractionated Plasma Products Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Fractionated Plasma Products Sales Value by Type (2021-2032)
- 4.2.3 Global Fractionated Plasma Products Sales Value Share by Type (2021-2032)
5 Fractionated Plasma Products Market by Application
- 5.1 Fractionated Plasma Products Application Introduction
- 5.1.1 Immunology
- 5.1.2 Hematology
- 5.1.3 Other
- 5.2 Global Fractionated Plasma Products Sales Value by Application
- 5.2.1 Global Fractionated Plasma Products Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Fractionated Plasma Products Sales Value by Application (2021-2032)
- 5.2.3 Global Fractionated Plasma Products Sales Value Share by Application (2021-2032)
6 Fractionated Plasma Products Regional Value Analysis
- 6.1 Global Fractionated Plasma Products Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Fractionated Plasma Products Sales Value by Region (2021-2032)
- 6.2.1 Global Fractionated Plasma Products Sales Value by Region: 2021-2026
- 6.2.2 Global Fractionated Plasma Products Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Fractionated Plasma Products Sales Value (2021-2032)
- 6.3.2 North America Fractionated Plasma Products Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Fractionated Plasma Products Sales Value (2021-2032)
- 6.4.2 Europe Fractionated Plasma Products Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Fractionated Plasma Products Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Fractionated Plasma Products Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Fractionated Plasma Products Sales Value (2021-2032)
- 6.6.2 South America Fractionated Plasma Products Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Fractionated Plasma Products Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Fractionated Plasma Products Sales Value Share by Country, 2025 VS 2032
7 Fractionated Plasma Products Country-level Value Analysis
- 7.1 Global Fractionated Plasma Products Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Fractionated Plasma Products Sales Value by Country (2021-2032)
- 7.2.1 Global Fractionated Plasma Products Sales Value by Country (2021-2026)
- 7.2.2 Global Fractionated Plasma Products Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.7.2 France Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.14.2 China Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.17.2 India Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Fractionated Plasma Products Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Fractionated Plasma Products Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Fractionated Plasma Products Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Takeda
- 8.1.1 Takeda Company Information
- 8.1.2 Takeda Business Overview
- 8.1.3 Takeda Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.1.4 Takeda Fractionated Plasma Products Product Portfolio
- 8.1.5 Takeda Recent Developments
- 8.2 Weiguang Bio
- 8.2.1 Weiguang Bio Company Information
- 8.2.2 Weiguang Bio Business Overview
- 8.2.3 Weiguang Bio Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.2.4 Weiguang Bio Fractionated Plasma Products Product Portfolio
- 8.2.5 Weiguang Bio Recent Developments
- 8.3 Tiantan Bio
- 8.3.1 Tiantan Bio Company Information
- 8.3.2 Tiantan Bio Business Overview
- 8.3.3 Tiantan Bio Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.3.4 Tiantan Bio Fractionated Plasma Products Product Portfolio
- 8.3.5 Tiantan Bio Recent Developments
- 8.4 Hualan Bio
- 8.4.1 Hualan Bio Company Information
- 8.4.2 Hualan Bio Business Overview
- 8.4.3 Hualan Bio Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.4.4 Hualan Bio Fractionated Plasma Products Product Portfolio
- 8.4.5 Hualan Bio Recent Developments
- 8.5 Yuanda Shuyang
- 8.5.1 Yuanda Shuyang Company Information
- 8.5.2 Yuanda Shuyang Business Overview
- 8.5.3 Yuanda Shuyang Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.5.4 Yuanda Shuyang Fractionated Plasma Products Product Portfolio
- 8.5.5 Yuanda Shuyang Recent Developments
- 8.6 Shuanglin Bio
- 8.6.1 Shuanglin Bio Company Information
- 8.6.2 Shuanglin Bio Business Overview
- 8.6.3 Shuanglin Bio Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.6.4 Shuanglin Bio Fractionated Plasma Products Product Portfolio
- 8.6.5 Shuanglin Bio Recent Developments
- 8.7 RAAS
- 8.7.1 RAAS Company Information
- 8.7.2 RAAS Business Overview
- 8.7.3 RAAS Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.7.4 RAAS Fractionated Plasma Products Product Portfolio
- 8.7.5 RAAS Recent Developments
- 8.8 Octapharma
- 8.8.1 Octapharma Company Information
- 8.8.2 Octapharma Business Overview
- 8.8.3 Octapharma Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.8.4 Octapharma Fractionated Plasma Products Product Portfolio
- 8.8.5 Octapharma Recent Developments
- 8.9 Nanyue Bio
- 8.9.1 Nanyue Bio Company Information
- 8.9.2 Nanyue Bio Business Overview
- 8.9.3 Nanyue Bio Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.9.4 Nanyue Bio Fractionated Plasma Products Product Portfolio
- 8.9.5 Nanyue Bio Recent Developments
- 8.10 LFB Group
- 8.10.1 LFB Group Company Information
- 8.10.2 LFB Group Business Overview
- 8.10.3 LFB Group Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.10.4 LFB Group Fractionated Plasma Products Product Portfolio
- 8.10.5 LFB Group Recent Developments
- 8.11 KM Biologics
- 8.11.1 KM Biologics Company Information
- 8.11.2 KM Biologics Business Overview
- 8.11.3 KM Biologics Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.11.4 KM Biologics Fractionated Plasma Products Product Portfolio
- 8.11.5 KM Biologics Recent Developments
- 8.12 Kedrion
- 8.12.1 Kedrion Company Information
- 8.12.2 Kedrion Business Overview
- 8.12.3 Kedrion Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.12.4 Kedrion Fractionated Plasma Products Product Portfolio
- 8.12.5 Kedrion Recent Developments
- 8.13 Grifols
- 8.13.1 Grifols Company Information
- 8.13.2 Grifols Business Overview
- 8.13.3 Grifols Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.13.4 Grifols Fractionated Plasma Products Product Portfolio
- 8.13.5 Grifols Recent Developments
- 8.14 CSL
- 8.14.1 CSL Company Information
- 8.14.2 CSL Business Overview
- 8.14.3 CSL Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.14.4 CSL Fractionated Plasma Products Product Portfolio
- 8.14.5 CSL Recent Developments
- 8.15 CBPO
- 8.15.1 CBPO Company Information
- 8.15.2 CBPO Business Overview
- 8.15.3 CBPO Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.15.4 CBPO Fractionated Plasma Products Product Portfolio
- 8.15.5 CBPO Recent Developments
- 8.16 BPL
- 8.16.1 BPL Company Information
- 8.16.2 BPL Business Overview
- 8.16.3 BPL Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.16.4 BPL Fractionated Plasma Products Product Portfolio
- 8.16.5 BPL Recent Developments
- 8.17 Boya Bio
- 8.17.1 Boya Bio Company Information
- 8.17.2 Boya Bio Business Overview
- 8.17.3 Boya Bio Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.17.4 Boya Bio Fractionated Plasma Products Product Portfolio
- 8.17.5 Boya Bio Recent Developments
- 8.18 Biotest
- 8.18.1 Biotest Company Information
- 8.18.2 Biotest Business Overview
- 8.18.3 Biotest Fractionated Plasma Products Revenue and Gross Margin (2021-2026)
- 8.18.4 Biotest Fractionated Plasma Products Product Portfolio
- 8.18.5 Biotest Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst